Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00075829 · OUTCOME

Progression-Free Survival (PFS)

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) · Source last updated 2021-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
Year 3

What was measured

Patients are considered a failure for this endpoint if they die or if they progress or relapse.

Analysis population: Patients that completed second transplant

Groups in this outcome

Auto-Auto Standard Risk

Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients

Auto-Allo Standard Risk

Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients

Auto-Auto High Risk

Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients

Auto-Allo High Risk

Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Auto-Auto Standard Risk366
Auto-Allo Standard Risk156
Auto-Auto High Risk31
Auto-Allo High Risk29

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Auto-Auto Standard Risk46Not reported4251Not reported
Auto-Allo Standard Risk43Not reported3651Not reported
Auto-Auto High Risk33Not reported2250Not reported
Auto-Allo High Risk40Not reported2760Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        42
        upper Limit
        51
        value
        46
      2. group Id
        OG001
        lower Limit
        36
        upper Limit
        51
        value
        43
      3. group Id
        OG002
        lower Limit
        22
        upper Limit
        50
        value
        33
      4. group Id
        OG003
        lower Limit
        27
        upper Limit
        60
        value
        40
denoms
  1. counts
    1. group Id
      OG000
      value
      366
    2. group Id
      OG001
      value
      156
    3. group Id
      OG002
      value
      31
    4. group Id
      OG003
      value
      29
    units
    Participants
description
Patients are considered a failure for this endpoint if they die or if they progress or relapse.
dispersion Type
95% Confidence Interval
groups
  1. description
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients
    id
    OG000
    title
    Auto-Auto Standard Risk
  2. description
    Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
    id
    OG001
    title
    Auto-Allo Standard Risk
  3. description
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients
    id
    OG002
    title
    Auto-Auto High Risk
  4. description
    Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
    id
    OG003
    title
    Auto-Allo High Risk
param Type
NUMBER
population Description
Patients that completed second transplant
reporting Status
POSTED
time Frame
Year 3
title
Progression-Free Survival (PFS)
type
PRIMARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice